A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function
Completed · Phase 1
Conditions studied: Hepatic Impairment
In brief
This is a phase 1, open-label, single-dose, parallel-cohort study to determine the pharmacokinetics (PK) of divarasib in healthy participants and participants with varying degrees of hepatic impairment, as defined by Child-Pugh classification.
Key facts
- Study ID
- NCT06734208
- Run by
- Genentech, Inc.
- People needed
- 31
- Starts
- 2025-01-31
- Expected to finish
- 2025-11-27
- Last updated by the study team
- 2025-12-04
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami, Inc. — Miami, Florida, United States
- Panax Clinical Research, LLC — Miami Lakes, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- American Research Corporation Inc. — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.